The genetic gap: how APOE4 damages brain vessels
The APOE4 gene variant can not only increase the likelihood of developing Alzheimer's disease, but also directly trigger damage to brain vessels and disrupt the removal of potentially dangerous proteins. This is the conclusion reached by researchers at the Aikan Medical School at the Mount Sinai Health System. About how APOE4 changes the cells of the vascular system, what cholesterol has to do with it and whether the detected violations can be reversed, see the "Izvestia" material.
Vascular trace of Alzheimer's disease
Alzheimer's disease is a progressive neurodegenerative disease in which a person's memory, thinking, and ability to perform everyday tasks gradually deteriorate. In the United States alone, more than 7 million elderly people live with this disorder.
Abnormal forms of proteins, including beta-amyloid and tau protein, accumulate in the brain of patients. At the same time, blood vessels are damaged and the blood—brain barrier, a system that separates brain tissue from the general bloodstream and protects it from potentially harmful substances, is disrupted.
For a long time, vascular disorders were considered primarily as one of the late consequences of the disease. However, the results of two new studies indicate that vascular damage may be not only the result of neurodegeneration, but also an independent participant in the pathological process.
Such changes were especially pronounced in the presence of APOE4. We are not talking about a separate "Alzheimer's disease gene", but about one of the variants of the APOE gene, which is responsible for the creation of apolipoprotein E and is involved in the transfer of lipids, including cholesterol.
The main variants of this gene are APOE2, APOE3 and APOE4. APOE3 is most common, APOE2 in some cases is associated with a reduced likelihood of Alzheimer's disease, and APOE4 is considered the most significant genetic risk factor for its late form. According to the US National Institute of Aging, approximately 25% of people have one copy of APOE4, and another 2-3% have two copies. However, the presence of such an option does not mean that the disease will necessarily develop.
How APOE4 changes the purpose of cells
In the first paper, published in the journal Cell, the researchers focused on the vascular system of the brain. They combined previously obtained data and created a single—cell transcriptomic atlas, a detailed map of the activity of genes in cells that form and maintain brain vessels.
This approach made it possible to compare the state of individual cell populations and track which changes are associated with APOE4. One of the main results was the discovery of an unusual transformation of pericytes.
Pericytes are located along small vessels and capillaries. They support the vascular wall, are involved in regulating blood flow, and help maintain the integrity of the blood-brain barrier. In a normal state, these cells literally cover the vessels and ensure the stability of their structure.
With APOE4, the number of pericytes decreased. At the same time, a population of myofibroblast-like cells appeared, which produced extracellular matrix components and were capable of causing tissue scarring.
The scientists concluded that the pericytes did not just disappear: some of them passed into a different state and acquired the properties of myofibroblasts. Instead of supporting the vessels, such cells began to actively secrete fibronectin, an extracellular matrix protein involved in the formation of scar tissue.
As a result, fibrosis developed around the vessels, and amyloid accumulated on and near their walls. Such changes can disrupt the blood supply to the brain, weaken the vascular system and create additional conditions for the death of nerve cells.
"Damage to the blood vessels of the brain is not just a late consequence of Alzheimer's disease. This is a biologically active process caused by APOE4, which can potentially be reversible," said Joel Blanchard, one of the leaders of the research, associate professor of neurobiology, stem cell biology and regenerative medicine at the Icahn School of Medicine at Mount Sinai.
According to him, the results of the work indicate new possible targets for preserving vascular functions and limiting amyloid accumulation.
Scientists have found a vascular damage switch
One of the key participants in the discovered process turned out to be the signaling pathway of TGF-β, or transforming growth factor beta. This system of cellular communication regulates the repair and restructuring of tissues, the response of cells to damage and the formation of extracellular matrix components.
The increased activity of TGF-β pushed the pericytes to transition to a myofibroblast-like state. In other words, the cells that were supposed to support the vascular wall began to participate in its scarring.
The researchers tested whether it is possible to stop this process. After blocking the TGF-β signals, the number of pericytes around the vessels was restored, and the severity of fibrosis and accumulation of vascular amyloid decreased to levels comparable to those in the APOE3 variant.
This result was reproduced not only in human tissue created in the laboratory, but also in old mice with APOE4. According to the authors, this indicates that APOE4-related vascular disorders can be reversible at least at a certain stage.
Braxton Schuldt, the first author of the study, explained that the scientists managed to block the process by which the cells supporting the vessels turned into cells producing scar tissue. This reduced the accumulation of amyloid around blood vessels and allowed us to identify a possible way to protect the blood circulation of the brain in people with high genetic risk.
However, the blocking of TGF-β has so far been studied only in preclinical models. This signaling pathway is involved in a variety of processes throughout the body, so its suppression in humans can have consequences that the laboratory model does not reproduce. Before starting clinical use, it is necessary to determine how selectively this mechanism can be affected and whether such an intervention would be safe.
Cholesterol disrupted cellular cleaning
In the second study, published in Cell Stem Cell, the scientists used miBrains to study another mechanism related to APOE4, alpha-synuclein accumulation. This protein is present in the nervous system and normally participates in the work of neurons. Its pathological forms are capable of sticking together and forming intracellular inclusions. Such disorders are most closely associated with Parkinson's disease and dementia with Lewy bodies, however, alpha-synuclein changes can occur in other neurodegenerative diseases.
In the models with APOE4, the level of pathological alpha-synuclein was higher than in the models with APOE3. A series of experiments have shown that astrocytes, auxiliary cells of the nervous system that support neurons, regulate metabolism, and are involved in the removal of cellular waste, play a central role in this process.
APOE4 led to excessive accumulation of cholesterol inside astrocytes. Because of this, the endolysosomal system, a complex of intracellular structures responsible for sorting, processing and destroying unnecessary molecules, was disrupted.
Lysosomes can be conventionally called a cell recycling system. They break down damaged components and proteins that should no longer remain inside the cell. When excess cholesterol disrupted the functioning of this system, astrocytes lost their ability to fully process soluble alpha-synuclein.
The protein accumulated, acquired pathological properties, and then contributed to the formation of inclusions in neurons. Single-cell sequencing also revealed related changes in gene activity in different cell populations.
Thus, the researchers restored another chain of disorders: APOE4 caused the accumulation of cholesterol in astrocytes, excess lipids damaged the cellular recycling system, and a decrease in the ability to cleave alpha-synuclein contributed to its pathological spread. The data obtained indicate two potential therapeutic targets at once — the exchange and movement of cholesterol inside astrocytes, as well as the restoration of lysosome function.
We are not talking about cholesterol in the blood
The results of the study do not mean that the discovered mechanism can be stopped solely by diet or lowering cholesterol levels in the blood. Scientists have studied disorders in the distribution and processing of lipids inside a certain type of brain cells.
Cholesterol is necessary for the nervous system: it is involved in the creation of cell membranes, the formation of myelin and the transmission of signals between cells. The problem in this case was not the presence of this substance itself, but its pathological accumulation inside astrocytes and the resulting disruption of lysosomes.
The work also does not prove that APOE4 necessarily leads to Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies. This option increases the risk, but it is neither the sole cause of the disease nor an independent diagnosis. Age, other genetic characteristics, the state of the vascular system, and external factors are important.
Scientists are closer to personal trials
Another result was the ability to freeze miBrains with a predefined set of cells and risk factors. After defrosting, such samples can be used in subsequent experiments.
Louise Mesentier-Lawro, the first author of the work at Cell Stem Cell, associate professor of Neurobiology, Stem cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai, noted that cryopreservation increases the reproducibility of experiments and allows for scaling modeling of complex diseases.
This is especially important for testing medicinal compounds. If models of the same series can be stored and used at different times, researchers will be able to compare drugs under more controlled conditions and verify the results in independent experiments.
The Mount Sinai team also creates and freezes miBrains from the cells of specific patients. In the future, such models can help study individual mechanisms of disease development and evaluate in advance the reaction of cells of a certain person to experimental drugs.
According to Blanchard, the ability to test potential treatments early could narrow the gap between laboratory discoveries and the development of therapies for neurodegenerative disorders.
What does the discovery change in the study of Alzheimer's disease?
Two studies show that the effect of APOE4 is not limited to one pathological protein or one cell type. This option simultaneously affects the vascular support of the brain, the formation of the extracellular matrix, cholesterol metabolism and the protein waste disposal system.
In the first case, the target may be the transition of pericytes to a myofibroblast-like state under the action of TGF-β. The second is the accumulation of cholesterol in astrocytes and the resulting disruption of lysosomal function.
Of particular importance is the fact that some of the changes have been weakened. After blocking TGF-β, vascular pericyte coverage was restored and fibrosis and amyloid accumulation decreased. This allows us to consider the vascular system not only as an affected party, but also as a potential point of therapeutic intervention.
However, the studies were not clinical trials. The scientists worked with laboratory models of human tissue, postmortem samples and mice. It is unknown whether the identified mechanisms will be equally reversible in the brain of a living person, at what stage of the disease the intervention may be effective and whether it will be possible to affect the necessary cells without disrupting other body functions.
Therefore, the discovery does not yet provide a ready-made treatment method. Its main value lies in a more accurate understanding of how genetic risk translates into specific cellular damage, and in the emergence of targets that can now be consistently tested in drug development.
Переведено сервисом «Яндекс Переводчик»